New Data Show One in 31 Kids Has Autism
Autism prevalence in the U.S. has increased from one in 36 children to one in 31, according to the Centers for Disease Control and Prevention’s (CDC) latest Autism and Developmental Disabilities Monitoring (ADDM) Network survey.
COVID-19 May Increase IVIG-Resistance in Kids Prior to Developing Kawasaki Disease
A recent study found there is significantly higher intravenous immune globulin (IVIG) resistance among children who contracted COVID-19 before developing Kawasaki disease
University of Toledo Awarded Funds to Explore Immune Response to Oral Thrush
The University of Toledo will receive $473,632 from the National Institute of Dental and Craniofacial Research to explore how the body’s immune system responds to the condition known as oral thrush.
Activating B Cells Key to TIL Cancer Therapy Effectiveness
Researchers at Moffitt Cancer Center have found that tapping into the body’s own immune system and activating a type of immune cell known as B cells could be the key to boosting the effectiveness of tumor-infiltrating lymphocyte, or TIL therapy.
Draft Budget Proposal Would Cut HHS Federal Health Programs by One-Third
A draft budget proposal circulating among federal officials suggests a cut in the U.S. Department of Health and Human Services’ discretionary spending by as much as one-third, or tens of billions of dollars.
HHS and NIH Invest in Universal Vaccine Platform for Pandemic-Prone Viruses
The U.S. Department of Health and Human Services (HHS) and the National Institutes of Health (NIH) have announced the development of the next-generation, universal vaccine platform, Generation Gold Standard, using a beta-propiolactone (BPL)-inactivated, whole-virus platform.
Moderna’s Flu Vaccine Shows Positive Late-Stage Trial Results
Moderna’s experimental mRNA-based influenze (flu) vaccine produced a stronger immune response than a currently available vaccine in a late-stage trial, clearing a path forward for the product and the company’s separate combination flu and COVID vaccine.
FDA Approves Gammagard Liquid ERC to Treat PI, Plans to Discontinue Gammagard SD in December 2027
The U.S. Food and Drug Administration (FDA) has approved GAMMAGARD LIQUID ERC [immune globulin infusion (human)] with less than or equal to 2 µg/mL IgA in a 10% solution, the only ready-to-use liquid immunoglobulin (IG) therapy with low immunoglobulin A (IgA) content, as replacement therapy for individuals 2 years of age and older with primary immunodeficiency (PI).
Vaccine Safety Dominates Office Visit Concerns
Primary care physicians need considerable help winning the vaccine war given the limited amount of time they have to make their case in the exam room, according to the authors of a new study published online April 15 in the American Journal of Preventive Medicine.
Vaccine Advisers Recommend New RSV Vaccine for Infants
A group of outside advisers to the Centers for Disease Control and Prevention (CDC) voted 5-2 to recommend the use of Merck’s new antibody vaccine, Enflonsia (clesrovimab), that can protect babies from respiratory syncytial virus (RSV).